Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Algeta Signs Exclusive License Agreement with Lumiphore, Inc.

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
Algeta ASA has exercised its option to take an exclusive, worldwide license to patented Lumi4® bi-functional chelator technology from Lumiphore, Inc.

These technologies are currently being developed by Algeta to conjugate thorium-227 to tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs).

Lumiphore’s Lumi4® technology is based on a unique class of bi-functional chelators that forms a novel cage structure surrounding and tightly binding thorium-227, which can then be covalently attached to a range of tumor-targeting molecules, such as monoclonal antibodies, to create potential cancer therapeutics. Algeta originally signed an option/license agreement with Lumiphore around this technology in 2010 and subsequently extended it to enable further evaluation to be conducted. This stage of evaluation has now been completed successfully.

In parallel with this license agreement, Algeta has also been granted a license by Lumiphore covering a second class of bi-functional chelators that bind strongly to thorium-227, with the option of including a further selection of compounds within that license if future exploratory work confirms their promise.

Under the terms of the agreements, Algeta will pay Lumiphore the option exercise fee for the Lumi4® chelators, and a signature and option fee for the second class of chelators, plus development and sales milestones and a royalty on product sales. Further financial details have not been disclosed.

Thomas Ramdahl, Algeta’s Chief Technology Officer, said: “Algeta is assembling a broad portfolio of proprietary technologies (including bi-functional chelators, linkers and tumor-targeting molecules), intellectual property and expertise as a platform for generating Targeted Thorium Conjugates, or TTCs. The addition of the Lumiphore technologies to the portfolio through this license and further option agreements will ensure that we have access to the best bi-functional chelators for thorium-227 as we seek to create a pipeline of TTCs designed to address multiple high-value opportunities in targeted cancer therapy.”

Algeta’s TTC strategy is based on gaining access to carefully selected tumor-targeting molecules, via in-licensing, collaboration or via third parties, to which it links thorium-227 thereby creating potential new therapeutics. Algeta’s disclosed TTC programs include collaborations with Sanofi and Ablynx; programs based on CD22- (hematological cancer) and HER2-targeting (breast/ovarian cancer) molecules in-licensed from Immunomedics and Affibody, respectively; and a fully owned TTC program targeting hematological cancers. Algeta is advancing its preclinical pipeline with the aim of entering its first TTC into clinical trials in 2014.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Immune-Cell Traps May Aid Cancer Metastasis
Study suggests cancer cells can induce neutrophils to release traps which the cells use to capture pathogens.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
New Regulator of Immune Reaction Discovered
Calcium signal in cell nucleus regulates not only many brain functions but also defence reactions of the immune system.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Cell’s ‘Built-In Circuit’ Help Prevent Tumour Growth
Researchers have created cells with a 'built-in genetic circuit' that inhibits tumour growth.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Common Virus Helps Fight Liver Cancer
Reovirus, a cause of childhood colds, stimulates the immune system to kill cancerous cells.
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!